Cryoport posted Q4 FY 2025 total revenue of USD 45.5 million (+10%), including Life Sciences Services revenue of USD 25.0 million (+16%) and Life Sciences Products revenue of USD 20.4 million (+2%). Q4 FY 2025 loss from continuing operations was USD 8.5 million, with net loss of USD 11.6 million; adjusted EBITDA from continuing operations was negative USD 1.4 million. Q4 gross margin was 47.8%. For FY 2025, Cryoport reported total revenue of USD 176.2 million (+12%), with Life Sciences Services revenue of USD 96.5 million (+18%) and Life Sciences Products revenue of USD 79.7 million (+7%). FY 2025 loss from continuing operations was USD 34.0 million, while net income was USD 78.3 million, primarily driven by USD 112.3 million (net of taxes) from discontinued operations related to the divestiture of its CRYOPDP specialty courier business to DHL. Net income attributable to common stockholders was USD 70.3 million (USD 1.40 per share). FY 2025 adjusted EBITDA from continuing operations was negative USD 5.8 million, and FY gross margin was 47.1%. Cash, cash equivalents and short-term investments totaled USD 411.2 million at December 31, 2025. Cryoport guided FY 2026 revenue of USD 190.0 million to USD 194.0 million. Business updates included support for 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025, with commercial cell and gene therapy revenue of USD 33.4 million (+29%) and clinical-trial support revenue of USD 47.1 million (+14%) in FY 2025. The company highlighted the launch of a Global Supply Chain Center in Paris, onboarding of initial IntegriCell cryopreservation clients, and the launch of cGMP sterile fulfillment/kitting services in Liège, Belgium; it also cited ISO 21973:2020 certification for Cryoport Systems. In products, MVE introduced integrated condition monitoring for dry vapor shippers and launched the Fusion 800 Series cryogenic freezer. Cryoport also noted strategic collaborations with DHL, Cardinal Health and Parexel, and said it repurchased USD 10.0 million of shares in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cryoport Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603031605PR_NEWS_USPR_____LA00676) on March 03, 2026, and is solely responsible for the information contained therein.